Curaleaf Fires Back at Organigram-Aurora Deal, Accuses Aurora Board of Breaching Fiduciary Duties

By Nicolás Rodríguez, Managing Editor

Curaleaf Holdings (TSX: CURA; OTCQX: CURLF) has responded sharply to the proposed acquisition of Aurora Cannabis (NASDAQ: ACB; TSX: ACB) by Organigram Global (NASDAQ: OGI; TSX: OGI), insisting that its own competing takeover offer remains outstanding and accusing Aurora’s board of failing to protect shareholder interests.

In a statement issued Tuesday, Curaleaf maintained that its enhanced October 6 proposal offers greater value, a stronger capital markets profile, faster execution and higher anticipated synergies than the Organigram transaction.

The response follows Organigram’s announcement of an agreement to acquire Aurora for C$7.80 per share, valuing the Canadian cannabis producer at approximately C$561 million (roughly US$400 million). Organigram says its proposal represents a 21% premium to Curaleaf’s competing bid, based on the companies’ stated valuation methodology.

Curaleaf challenged the transparency of the new agreement, pointing to several outstanding questions, including potential termination fees, the future composition of the combined company’s management and board, and investor rights granted to British American Tobacco (BAT), Organigram’s major strategic shareholder.

The company also criticized the absence of explicit disclosure regarding whether the transaction would be accretive or dilutive to shareholders.

The strongest criticism concerned Aurora’s board. Curaleaf accused directors of granting Organigram access to confidential due diligence materials while denying similar access to Curaleaf, potentially preventing the company from improving its offer.

Curaleaf characterized that decision as a “gross dereliction of their fiduciary duties,” an allegation made by the bidder rather than an established legal finding.

The company further described Organigram as smaller, less liquid and vulnerable to shareholder dilution, questioning the financial strength of the proposed combination. Those characterizations reflect Curaleaf’s position in the ongoing takeover dispute.

For Aurora shareholders, the competing proposals now present different combinations of cash consideration, equity exposure and potential participation in international cannabis markets.

Despite Aurora’s agreement with Organigram, Curaleaf has not withdrawn its hostile bid, leaving the takeover contest unresolved as shareholders evaluate the competing transactions.

The competing bids for Aurora underscore the consolidation pressures reshaping the cannabis industry, from access to capital and shareholder value to the growing importance of international markets. These developments, alongside the evolving federal policy landscape, will be part of the conversation at IgniteIt’s Cannabis Capital & Policy Summit in Washington, D.C.⁠ on November 18, where industry executives, investors and policymakers will examine the forces shaping the sector’s next chapter.